Enhanced targeted drug delivery to hepatocellular carcinoma using Cucurbit[6]uril-modified ZIF-8 nanoparticle.

IF 2.3 4区医学 Q3 ENGINEERING, BIOMEDICAL Journal of Biomaterials Applications Pub Date : 2024-12-07 DOI:10.1177/08853282241306836

Mu-Yue Zheng, Hao Zheng, Yan Zeng, Tong Sun, Fang-Zhong Zhang, Yu-Lin Wang, Hai-Shuang Wang, Rong-Guang Lin

{"title":"Enhanced targeted drug delivery to hepatocellular carcinoma using Cucurbit[6]uril-modified ZIF-8 nanoparticle.","authors":"Mu-Yue Zheng, Hao Zheng, Yan Zeng, Tong Sun, Fang-Zhong Zhang, Yu-Lin Wang, Hai-Shuang Wang, Rong-Guang Lin","doi":"10.1177/08853282241306836","DOIUrl":null,"url":null,"abstract":"<p><p>Building on our innovative approach to combatting cancer, this study explores the development of a sophisticated hybrid nanocarrier system leveraging the unique properties of allyl oxide cucurbit[6]uril with galactose clusters (AOQ[6]@Gal) to modify ZIF-8 nanoparticles. These nanoparticles are designed to encapsulate and efficiently deliver the anticancer drugs doxorubicin (DOX) and curcumin (CUR), enhancing their water solubility and stability, while also providing active targeting towards hepatocellular carcinoma cells. The comprehensive characterization of AOQ[6]@Gal@ZIF-8@Drug nanoparticles revealed promising outcomes, including drug loading efficiencies of 9.7% for DOX and 8.3% for CUR, alongside a pH-responsive release profile that ensures effective drug delivery in the tumor microenvironment. Cytotoxicity studies underscored the hybrid system's superior safety profile, exhibiting minimal toxicity towards normal hepatocytes HL7702 and pronounced cytotoxic effects against hepatocellular carcinoma cells HepG2. These results highlight the hybrid nanocarrier's potential as a targeted, efficient, and safe platform for the delivery of chemotherapy agents in the treatment of liver cancer.</p>","PeriodicalId":15138,"journal":{"name":"Journal of Biomaterials Applications","volume":" ","pages":"8853282241306836"},"PeriodicalIF":2.3000,"publicationDate":"2024-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Biomaterials Applications","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1177/08853282241306836","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}

引用次数: 0

Abstract

Building on our innovative approach to combatting cancer, this study explores the development of a sophisticated hybrid nanocarrier system leveraging the unique properties of allyl oxide cucurbit[6]uril with galactose clusters (AOQ[6]@Gal) to modify ZIF-8 nanoparticles. These nanoparticles are designed to encapsulate and efficiently deliver the anticancer drugs doxorubicin (DOX) and curcumin (CUR), enhancing their water solubility and stability, while also providing active targeting towards hepatocellular carcinoma cells. The comprehensive characterization of AOQ[6]@Gal@ZIF-8@Drug nanoparticles revealed promising outcomes, including drug loading efficiencies of 9.7% for DOX and 8.3% for CUR, alongside a pH-responsive release profile that ensures effective drug delivery in the tumor microenvironment. Cytotoxicity studies underscored the hybrid system's superior safety profile, exhibiting minimal toxicity towards normal hepatocytes HL7702 and pronounced cytotoxic effects against hepatocellular carcinoma cells HepG2. These results highlight the hybrid nanocarrier's potential as a targeted, efficient, and safe platform for the delivery of chemotherapy agents in the treatment of liver cancer.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

利用瓜氨酸修饰的ZIF-8纳米颗粒增强肝癌靶向药物递送。

在我们对抗癌症的创新方法的基础上，本研究探索了一种复杂的混合纳米载体体系的开发，利用半乳糖簇（AOQ[6]@Gal）的独特性质来修饰ZIF-8纳米颗粒。这些纳米颗粒被设计用来包裹和有效地递送抗癌药物阿霉素（DOX）和姜黄素（CUR），提高它们的水溶性和稳定性，同时也为肝癌细胞提供主动靶向。AOQ b[6]@Gal@ZIF-8@药物纳米颗粒的综合表征显示了有希望的结果，包括DOX的载药效率为9.7%，CUR的载药效率为8.3%，以及ph响应释放谱，确保在肿瘤微环境中有效的药物递送。细胞毒性研究强调了混合系统优越的安全性，对正常肝细胞HL7702的毒性最小，对肝癌细胞HepG2的细胞毒性明显。这些结果突出了混合纳米载体作为肝癌化疗药物靶向、高效和安全平台的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Biomaterials Applications 工程技术-材料科学：生物材料

CiteScore

5.10

自引率

3.40%

发文量

144

审稿时长

1.5 months

期刊介绍： The Journal of Biomaterials Applications is a fully peer reviewed international journal that publishes original research and review articles that emphasize the development, manufacture and clinical applications of biomaterials. Peer-reviewed articles by biomedical specialists from around the world cover: New developments in biomaterials, R&D, properties and performance, evaluation and applications Applications in biomedical materials and devices - from sutures and wound dressings to biosensors and cardiovascular devices Current findings in biological compatibility/incompatibility of biomaterials The Journal of Biomaterials Applications publishes original articles that emphasize the development, manufacture and clinical applications of biomaterials. Biomaterials continue to be one of the most rapidly growing areas of research in plastics today and certainly one of the biggest technical challenges, since biomaterial performance is dependent on polymer compatibility with the aggressive biological environment. The Journal cuts across disciplines and focuses on medical research and topics that present the broadest view of practical applications of biomaterials in actual clinical use. The Journal of Biomaterial Applications is devoted to new and emerging biomaterials technologies, particularly focusing on the many applications which are under development at industrial biomedical and polymer research facilities, as well as the ongoing activities in academic, medical and applied clinical uses of devices.